138 related articles for article (PubMed ID: 24077567)
21. Clinical validation of a customized multiple signature microarray for breast cancer.
Tan BK; Tan LK; Yu K; Tan PH; Lee M; Sii LH; Wong CY; Ho GH; Yeo AW; Chow PK; Koong HN; Yong WS; Lim DT; Ooi LL; Soo KC; Tan P
Clin Cancer Res; 2008 Jan; 14(2):461-9. PubMed ID: 18223220
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profile prospectively predicts peritoneal relapse after curative surgery of gastric cancer.
Takeno A; Takemasa I; Seno S; Yamasaki M; Motoori M; Miyata H; Nakajima K; Takiguchi S; Fujiwara Y; Nishida T; Okayama T; Matsubara K; Takenaka Y; Matsuda H; Monden M; Mori M; Doki Y
Ann Surg Oncol; 2010 Apr; 17(4):1033-42. PubMed ID: 20012501
[TBL] [Abstract][Full Text] [Related]
23. A nomogram to predict individual prognosis in node-negative breast carcinoma.
Mazouni C; Spyratos F; Romain S; Fina F; Bonnier P; Ouafik LH; Martin PM
Eur J Cancer; 2012 Nov; 48(16):2954-61. PubMed ID: 22658808
[TBL] [Abstract][Full Text] [Related]
24. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
Győrffy B; Benke Z; Lánczky A; Balázs B; Szállási Z; Timár J; Schäfer R
Breast Cancer Res Treat; 2012 Apr; 132(3):1025-34. PubMed ID: 21773767
[TBL] [Abstract][Full Text] [Related]
25. Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets.
Yao J; Zhao Q; Yuan Y; Zhang L; Liu X; Yung WK; Weinstein JN
PLoS One; 2012; 7(9):e45894. PubMed ID: 23029298
[TBL] [Abstract][Full Text] [Related]
26. Genes and functions from breast cancer signatures.
Huang S; Murphy L; Xu W
BMC Cancer; 2018 Apr; 18(1):473. PubMed ID: 29699511
[TBL] [Abstract][Full Text] [Related]
27. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
28. Favorable outcome associated with an IGF-1 ligand signature in breast cancer.
Mu L; Tuck D; Katsaros D; Lu L; Schulz V; Perincheri S; Menato G; Scarampi L; Harris L; Yu H
Breast Cancer Res Treat; 2012 May; 133(1):321-31. PubMed ID: 22297468
[TBL] [Abstract][Full Text] [Related]
29. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
De Preter K; Vermeulen J; Brors B; Delattre O; Eggert A; Fischer M; Janoueix-Lerosey I; Lavarino C; Maris JM; Mora J; Nakagawara A; Oberthuer A; Ohira M; Schleiermacher G; Schramm A; Schulte JH; Wang Q; Westermann F; Speleman F; Vandesompele J
Clin Cancer Res; 2010 Mar; 16(5):1532-41. PubMed ID: 20179214
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients.
Györffy B; Schäfer R
Breast Cancer Res Treat; 2009 Dec; 118(3):433-41. PubMed ID: 19052860
[TBL] [Abstract][Full Text] [Related]
31. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
Van Belle V; Van Calster B; Brouckaert O; Vanden Bempt I; Pintens S; Harvey V; Murray P; Naume B; Wiedswang G; Paridaens R; Moerman P; Amant F; Leunen K; Smeets A; Drijkoningen M; Wildiers H; Christiaens MR; Vergote I; Van Huffel S; Neven P
J Clin Oncol; 2010 Sep; 28(27):4129-34. PubMed ID: 20713855
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience.
Kim RG; Kim EK; Kim HA; Koh JS; Kim MS; Kim KI; Lee JI; Moon NM; Ko E; Noh WC
Eur J Surg Oncol; 2011 Jul; 37(7):629-34. PubMed ID: 21596514
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a novel platform-independent metastasis signature in human breast cancer.
Zhao SG; Shilkrut M; Speers C; Liu M; Wilder-Romans K; Lawrence TS; Pierce LJ; Feng FY
PLoS One; 2015; 10(5):e0126631. PubMed ID: 25974184
[TBL] [Abstract][Full Text] [Related]
34. A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer.
Biermann J; Nemes S; Parris TZ; Engqvist H; Rönnerman EW; Forssell-Aronsson E; Steineck G; Karlsson P; Helou K
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1619-1628. PubMed ID: 28877888
[No Abstract] [Full Text] [Related]
35. Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials.
Theilhaber J; Chiron M; Dreymann J; Bergstrom D; Pollard J
BMC Bioinformatics; 2020 Jul; 21(1):333. PubMed ID: 32711453
[TBL] [Abstract][Full Text] [Related]
36. Improved breast cancer prognosis through the combination of clinical and genetic markers.
Sun Y; Goodison S; Li J; Liu L; Farmerie W
Bioinformatics; 2007 Jan; 23(1):30-7. PubMed ID: 17130137
[TBL] [Abstract][Full Text] [Related]
37. Toward the precision breast cancer survival prediction utilizing combined whole genome-wide expression and somatic mutation analysis.
Zhang Y; Yang W; Li D; Yang JY; Guan R; Yang MQ
BMC Med Genomics; 2018 Nov; 11(Suppl 5):104. PubMed ID: 30454048
[TBL] [Abstract][Full Text] [Related]
38. Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer.
Song Q; Wang H; Bao J; Pullikuth AK; Li KC; Miller LD; Zhou X
Sci Rep; 2015 Aug; 5():12981. PubMed ID: 26257336
[TBL] [Abstract][Full Text] [Related]
39. Integration of pathway structure information into a reweighted partial Cox regression approach for survival analysis on high-dimensional gene expression data.
Liu W; Wang Q; Zhao J; Zhang C; Liu Y; Zhang J; Bai X; Li X; Feng H; Liao M; Wang W; Li C
Mol Biosyst; 2015 Jul; 11(7):1876-86. PubMed ID: 25891149
[TBL] [Abstract][Full Text] [Related]
40. Boosting the discriminatory power of sparse survival models via optimization of the concordance index and stability selection.
Mayr A; Hofner B; Schmid M
BMC Bioinformatics; 2016 Jul; 17():288. PubMed ID: 27444890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
